[mad_as_he$$]

Thanks for the offer. I was looking for the annual consumption per person numbers. Dosage doesn't seem to vary by much from country to country. Mostly it started with "Why(does it seem) that malaria regions aren't(seemingly) impacted by COVID-19 as Europe and the US.

[JayGalt]

I was looking for the number of doses yearly in the world. I didn’t find that. I will look for your question as well.

[JayGalt]

These studies are mostly related to finding out why some people had higher consumption than others. There was another study to calculate cost of prophylaxis based on dose/person. Malarial prophylaxis is episodic which may not be what you were looking for.

https://www.researchgate.net/figure/Age-pattern-of-annual-chloroquine-treatments-per-person-during-a-community-based-study-of_fig4_8451683

Age pattern of annual chloroquine treatments per person during a community-based study of improving access to antimalarial drugs in Saradidi, Kenya

https://www.researchgate.net/publication/19472968_Consumption_of_chloroquine_phosphate_provided_for_treatment_of_malaria_by_volunteer_village_health_workers_in_Saradidi_Kenya

Consumption of the drug and characteristics of persons treated were recorded. Between 1 September 1982 to 31 August 1983, 40,649 treatments with chloroquine were given to village residents. The treatment rate per person in the mid-year population was 1.24. However, at least 41.8% of the mid-year population of 32,650 did not receive a single treatment. Multiple treatments were given to 50.5% of persons treated at least once and 13.4% of 13,879 persons treated at least once received five or more treatments during the year. Consumption patterns were not random: they were higher in females, in persons above 30 years of age and in the area with greater community organization and community participation.